June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Baseline parameters of the HELP study (long-term observation of Caucasians with pathologic myopia): distribution of age in pre-defined risk categories for developing a myopic choroidal neovascularization
Author Affiliations & Notes
  • Charlotte Melzer
    Department of Opthalmology, University of Bonn, Grade Reading Center, Bonn, Germany
  • Focke Ziemssen
    Department of Ophtalmology, Eberhard Karl University Tuebingen, Tuebingen, Germany
  • Nicole Eter
    Department of Ophtalmology, University of Muenster, Muenster, Germany
  • Christian Karl Brinkmann
    Department of Opthalmology, University of Bonn, Grade Reading Center, Bonn, Germany
  • Hansjuergen Agostini
    Eye Center, University of Freiburg, Freiburg, Germany
  • Gisela Haeusser-Frueh
    Novartis Pharma, Nuremberg, Germany
  • Schargus Marc
    Schweinfurt Eye Hospital, Schweinfurt, Germany
  • Katrin Lorenz
    Department of Ophtalmology, University of Mainz, Mainz, Germany
  • Frank G Holz
    Department of Opthalmology, University of Bonn, Grade Reading Center, Bonn, Germany
  • Steffen Schmitz-Valckenberg
    Department of Opthalmology, University of Bonn, Grade Reading Center, Bonn, Germany
  • Footnotes
    Commercial Relationships   Charlotte Melzer, Heidelberg Engineering (F), Novartis Germany (F), Novartis Germany (R), Optos (F), Zeiss (F); Focke Ziemssen, Alcon (R), Alimera (C), Allergan (C), Allergan (R), Bayer Healthcare (C), Bayer Healthcare (R), Biogen (R), Boehringer-Ingelheim (C), Novartis Germany (C), Novartis Germany (R); Nicole Eter, Alimera (C), Allergan (C), Allergan (F), Allergan (R), Bausch and Lomb (C), Bayer (C), Bayer (F), Bayer (R), Heidelberg Engineering (R), Novartis Germany (C), Novartis Germany (F), Novartis Germany (R), Roche (C); Christian Brinkmann, Heidelberg Engeneering (F), Heidelberg Engineering (C), Newtricious (F), Newtricious (C), Novartis Germany (F), Novartis Germany (C), Zeiss Meditec (F); Hansjuergen Agostini, Novartis Germany (C), Novartis Germany (F); Gisela Haeusser-Frueh, Novartis Germany (E); Schargus Marc, None; Katrin Lorenz, Novartis Germany (C); Frank Holz, Acucela (F), Acucela (C), Allergan (F), Allergan (R), Bayer (F), Bayer (C), Bayer (R), Bioeq (F), Bioeq (C), Boehringer-Ingelheim (C), Gentech/Roche (F), Gentech/Roche (C), Gentech/Roche (R), Heidelberg Engeneering (F), Heidelberg Engeneering (C), Heidelberg Engeneering (R), Merz (C), NigtstarX (F), Novartis Germany (F), Novartis Germany (C), Novartis Germany (R), Optos (F), Thea (C), Zeiss (F), Zeiss (R); Steffen Schmitz-Valckenberg, Alcon/Novartis Germany (F), Alcon/Novartis Germany (C), Allergan (F), Allergan (R), Bayer (F), Bayer (R), Carl Zeiss MediTec (F), Formycon (F), Gentech/Roche (C), Gentech/Roche (F), Gentech/Roche (R), Heidelberg Engineering (F), Heidelberg Engineering (R), Optos (F)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 5489. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Charlotte Melzer, Focke Ziemssen, Nicole Eter, Christian Karl Brinkmann, Hansjuergen Agostini, Gisela Haeusser-Frueh, Schargus Marc, Katrin Lorenz, Frank G Holz, Steffen Schmitz-Valckenberg; Baseline parameters of the HELP study (long-term observation of Caucasians with pathologic myopia): distribution of age in pre-defined risk categories for developing a myopic choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 2017;58(8):5489.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : This German research project is a prospective observational study in Caucasians with pathologic myopia and pre-defined disease patterns. The intention is to assess the natural progression of this disease within three years and to identify potential risk factors for the development of myopic choroidal neovascularization (mCNV).

Methods : Initially it was planned to enroll 50 patients per risk group, in total 250 subjects in a multicenter approach. The inclusion criteria, five different morphological risk factors in the study eye, were approved by an independent central reading center (CRC). Apart from an axial length of ≥ 26 mm the pre-defined groups where defined as: (1) subfoveal choroidal thinning < 50 µm, (2) choroidal curvature length > 6300 µm, (3) lacquer cracks, (4) patchy atrophy > 5 mm2 and (5) preexisting mCNV in the fellow eye (German Clinical Trial Register DRKS00007761).

Results : After 2 years of recruitment, a total of 153 patients (66% females) with a mean age of 57.2 years (± 12.7), ranging from 21.9 to 86.2 years, were included . Age distribution was similar for the two groups subfoveal choroidal thinning and lacquer cracks, with a mean age of 57.1 (n=51) and 54.4 years (n=50) respectively. In the patchy atrophy group, data showed a shift in distribution to older patients (mean 63.7 years, n=22). Patients with preexisting mCNV in the fellow eye showed a mean age of 56.4 years (n=22). Furthermore it was shown that the risk factor choroidal curvature (5% of the total population, n= 8) was rarely found in the Caucasian population.

Conclusions : The HELP study is the first study that prospectively analyses risk factors for the development of mCNV in Caucasians in a large cohort. The data presented here suggest that the increased choroidal curvature, as defined by the protocol and described in the literature, is less frequent in Caucasians than in Asian population and the risk factor patchy atrophy might occur mainly in elderly Caucasian patients.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×